Comparison Between Lamivudine and Entecavir Treatment in Spontaneous Severe Acute Exacerbation (NUC115132)

Comparison Between Lamivudine and Entecavir Treatment in Patients With Spontaneous Severe Acute Exacerbation of Chronic Hepatitis B.

This is a prospective, observational, open-label, 2-arm, parallel, multi-center study. Patients with HBV-associated severe acute exacerbation for whom the treatment with NRTI (such as lamivudine and entecavir) is medically recommended will be screened for eligibility. To target 74 evaluable subjects, approximately 82 patients should be recruited into this trial. After enrollment, all eligible subjects will be randomly assigned to one of the antiviral treatments below. Cohort 1: Lamivudine 100 mg p.o. q.d. Cohort 2: Entecavir 0.5 mg p.o. q.d. This process will be stratified by prolonged PT, < 4 sec / 4-6 sec / > 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment. The efficacy and safety data will be collected at baseline, 3, 5, 8, 15, 22, 29, 85, and 180 days after initiation of antiviral treatment. All assessments should be conducted based on routine practice of each hospital. Only the analysis of HBV DNA and anti-HDV will be performed in the central lab. For patients who are willing to provide the residual samples of HBV DNA assessment, the blood samples will be preserved appropriately. All AE(s) and SAE will be followed until resolution or the event is considered stable.

The study is to compare treatment response of lamivudine and entecavir in patients with spontaneous severe acute exacerbation of chronic hepatitis B. 1. Primary objective: • To compare the overall survival (OS) rate during observational period between lamivudine and entecavir therapy. 2. Secondary objectives: To compare the change from baseline in HBV DNA level at each visit between lamivudine and entecavir therapy. To compare the proportion of subjects who have a ≥ 2 log10 decline from baseline in HBV DNA level at each visit between lamivudine and entecavir therapy. To compare the change from baseline in ALT and AST level at each visit between lamivudine and entecavir therapy. To compare the proportion of subjects with prolonged prothrombin time (PT) at each visit between lamivudine and entecavir therapy. To compare the change from baseline in bilirubin level at each visit between lamivudine and entecavir therapy. To compare the transplantation-free survival rate during observational period between lamivudine and entecavir therapy. To assess the safety of lamivudine and entecavir treatments in patients with HBV-associated severe acute exacerbation. Statistical method(s) for safety/efficacy evaluations: The major analysis will be performed according to the principal of intent-to-treat population; the safety evaluation will be performed according to the safety population. For primary endpoint, the time to event will be analyzed by Kaplan-Meier method and summarized as the number of observations, number of censored, median time point estimate and the 95% CI for median. Secondary efficacy endpoints: 1. Change from baseline in HBV DNA level at each visit 2. Proportion of subjects with HBV DNA response* at each visit Defined as a ≥ 2 log10 decline from baseline HBV DNA level. 3. Change from baseline in ALT level at each visit 4. Change from baseline in AST level at each visit 5. Proportion of subjects with prolonged PT* at each visit PT at each visit will also be assessed. 6. Change from baseline in bilirubin level at each visit 7. Transplantation-free survival rate during observational period Continuous variables will be analyzed using two-sample t-test/ Wilcoxon Rank Sum test, and categorical variables will be analyzed Chi-squared/ Fishers' exact test. Descriptive statistics including mean, standard deviation, median, minimum, maximum, 95% confidence interval will be also presented. Categorical variables will be summarized by counts and percentage in frequency table. In addition, the time to event will be analyzed by Kaplan-Meier method. (4) The summary results of laboratory at the baseline and the end of study visit, the change from baseline to end of study visit will be summarized by descriptive statistics and paired t-test will be used under significant level 0.05. (5) Adverse events will be coded with MedDRA and a summary frequency table of adverse events will be provided. The severity and relationship to study medication of adverse events will be summarized as well. Furthermore, if any serious adverse event had occurred, the brief summary about serious adverse event will be described and listed in tables. (6) All statistical tests will be two-side and evaluated at the 0.05 level of significance.

Spontaneous Severe Acute Exacerbation of Chronic Hepatitis B, Lamivudine (Zeffix®), Entecavir (Baraclude®)

To target 88 evaluable subjects, approximately 98 patients should be recruited into this trial. After enrollment, all eligible subjects will be randomly assigned to one of the antiviral treatments below. Cohort 1: Lamivudine 100 mg p.o. q.d. Cohort 2: Entecavir 0.5 mg p.o. q.d. This process will be stratified by prolonged PT, < 4 sec / 4-6 sec / > 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment.

To target 88 evaluable subjects, approximately 98 patients should be recruited into this trial. After enrollment, all eligible subjects will be randomly assigned to one of the antiviral treatments below. Cohort 1: Lamivudine 100 mg p.o. q.d. Cohort 2: Entecavir 0.5 mg p.o. q.d. This process will be stratified by prolonged PT, < 4 sec / 4-6 sec / > 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment.

Lamivudine 100 mg p.o. q.d. This process will be stratified by prolonged PT, < 4 sec / 4-6 sec / > 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment.

•Entecavir 0.5 mg p.o. q.d This process will be stratified by prolonged PT, < 4 sec / 4-6 sec / > 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment.

To compare the change from baseline in HBV DNA level at each visit during observational period between lamivudine and entecavir therapy.

To compare the proportion of subjects who have a ≥ 2 log10 decline from baseline in HBV DNA level at each visit between lamivudine and entecavir therapy.

To compare the change from baseline in ALT and AST level at each visit between lamivudine and entecavir therapy.

To compare the change from baseline in bilirubin level at each visit between lamivudine and entecavir therapy.

To compare the proportion of subjects with prolonged prothrombin time (PT) at each visit between lamivudine and entecavir therapy.

To compare the transplantation-free survival rate during observational period between lamivudine and entecavir therapy.

To assess the safety of lamivudine and entecavir treatments in patients with HBV-associated severe acute exacerbation.

Inclusion Criteria: Male or female ≥ 20 years of age HBsAg carrier with spontaneously severe acute exacerbation for whom the treatment with nucleoside and nucleotide reverse transcriptase inhibitor (NRTI) such as lamivudine and entecavir is medically recommended Patients who fulfills all of the following criteria at screening: documented HBsAg positive for at least 6 months or anti-HBc IgM negative HBV DNA ≥ 2,000 IU/mL* * The blood sample will be collected at screening visit, but this criterion will be checked after obtaining lab result. For patients fulfill all other criteria, they can be enrolled immediately. total bilirubin ≥ 2 mg/dL or prolonged prothrombin time (PT) ≥ 3 sec serum ALT ≥ 10 x ULN Patient with sufficient renal function defined as SCr ≤ 1.5 x ULN or ClCr ≥ 50 mL/min Willing and able to sign a written informed consent Exclusion Criteria: Female who is pregnant/lactating Patient with underlying liver cirrhosis classified as Child-Pugh class B or C Patients with documented hepatitis A virus (HAV), hepatitis C virus (HCV), hepatitis D virus (HDV) or human immunodeficiency virus (HIV) co-infection Patients with uncontrolled malignancy History or presence of alcohol or substance abuse within 1 year prior to the initiation of NRTI treatment History of hypersensitivity to any ingredient of observational drugs (Zeffix® or Baraclude®) Current use of medicine which may induce hepatotoxicity Use of any antiviral therapy for HBV, such as interferon-α (IFN-α) and other nucleotide/nucleoside analogues, within 6 months prior to the initiation of NRTI treatment or exposure to any treatment for more than 3 months Use of any chemotherapy or immunosuppressive agents within 12 months prior to the initiation of NRTI treatment Use of any investigational product, including drug and invasive medical device, within 4 weeks prior to the initiation of NRTI treatment Patient with any medical or psychiatric condition, including the presence of significant abnormal laboratory values, which is considered not suitable for this study by investigator

Lee TY, Chen CY, Lia HC, Hsu YC, Yang SS. The ultra-short virological dynamics in response to entecavir or lamivudine during chronic hepatitis B with spontaneous severe acute exacerbation. Antivir Ther. 2018;23(1):77-85. doi: 10.3851/IMP3183.